WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs) for cancer immunotherapy, and Cognate BioServices, a contract development and manufacturing organization (CDMO) in the global cellular therapies industry, have entered an agreement to expand WindMIL’s clinical manufacturing capacity.   “Our clinical program with MILs, including our ongoing Phase 2a trial in non-small-cell lung cancer (NSCLC), is growing rapidly,” said Don Hayden, chairman and chief e...